Yudi Her Oktaviono and Hanang Anugrawan Ahmad and Makhyan Jibril Al Farabi and Parama Gandi and Caesar Lagaliggo Givani and Indah Sari Purna Lumeno and Yusuf Azmi (2021) Enhancement of EPC migration by high-dose lisinopril is superior compared to captopril and ramipril [version 1; peer review: awaiting peer review]. F1000Research, 10 (15). pp. 1-10. ISSN 20461402

	Text (Artikel) Enhancement of EPC migration by high-dose lisinopril is superior compared to captopril and ramipril (version 1; peer review; awaiting peer review).pdf Download (1MB)
	Text (Bukti Korespondensi) bukti korespondensi f1000.pdf Download (496kB)
	Text (Peer Review) Enhancement of EPC.pdf Download (1MB)
	Text (Similarity) Enhancement of EPC migration by high-dose lisinopril is superior compared to captopril and ramipril (version 1; peer review; awaiting peer review).pdf Download (2MB)

Abstract

Background: Angiotensin-converting enzyme (ACE) inhibitors have been shown to promote endothelial progenitor cell (EPC) function. However, the efficacies of different ACE inhibitors in improving the migratory capabilities of ECPs in coronary artery disease (CAD) patients is unclear. This study compared the effectiveness of captopril, lisinopril, and ramipril toward the migration capability of impaired EPCs from CAD patients. Methods: We isolated peripheral blood mononuclear cells (PBMCs), separated EPCs from PBMCs, and divided them into an untreated group (control) and treated groups of captopril, lisinopril, and ramipril at doses of 1mM, 10mM, and 100mM. EPC migration was evaluated using the Boyden chamber assay. Analysis of variance (ANOVA) was performed using SPSS 25.0. Results: This study showed that treatment with captopril, lisinopril, and ramipril starting at the lowest dose (1 mM) increased EPC migration (65,250 ± 6,750 cells; 60,750± 5,030 cells; and 49,500 ± 8,400 cells, respectively) compared to control (43,714 ± 7,216 cells). Increased migration of EPCs was observed by increasing the treatment dose to 10 mM with captopril, lisinopril, and ramipril (90,000 ± 16,837 cells; 79,071 ± 2,043 cells; and 64,285 ± 11,824 cells, respectively). The highest EPC migration was shown for lisinopril 100 mM (150,750 ± 16,380 cells), compared to captopril and ramipril at the same dose (105,750 ± 8112 cells and 86,625 ± 5,845 cells, respectively). Conclusions: Captopril, ramipril, and lisinopril were shown to increase EPC migration in a dose-dependent manner. Low-dose (1 mM) and medium-dose (10 mM) captopril had a larger effect on ECP migration than lisinopril and ramipril. Meanwhile, high-dose lisinopril (100mM) had the highest migration effect, suggesting it may be preferable for promoting EPC migration in CAD patients.

Actions (login required)

View Item